125 related articles for article (PubMed ID: 27721547)
1. Incidence of atazanavir- associated adverse drug reactions in second -line drugs treated south Indian HIV-1 infected patients.
Subashini D; Dinesha TR; Boobalan J; Samuel LC; Poongulali S; Pradeep A; Solomon SS; Solomon S; Balakrishnan P; Saravanan S
Indian J Pharmacol; 2016; 48(5):582-585. PubMed ID: 27721547
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
Teófilo E; Rocha-Pereira N; Kuhlmann B; Antela A; Knechten H; Santos J; Jiménez-Expósito MJ;
HIV Clin Trials; 2016 Feb; 17(1):17-28. PubMed ID: 26899539
[TBL] [Abstract][Full Text] [Related]
4. Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
Gervasoni C; Meraviglia P; Minisci D; Ferraris L; Riva A; Landonio S; Cozzi V; Charbe N; Molinari L; Rizzardini G; Clementi E; Galli M; Cattaneo D
PLoS One; 2015; 10(4):e0123670. PubMed ID: 25875091
[TBL] [Abstract][Full Text] [Related]
5. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.
Torti C; Lapadula G; Antinori A; Quirino T; Maserati R; Castelnuovo F; Maggiolo F; De Luca A; Paraninfo G; Antonucci F; Migliorino G; Lazzarin A; Di Perri G; Rizzardini G; Esposito R; Carosi G
Infection; 2009 Jun; 37(3):244-9. PubMed ID: 19471856
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 Study.
Cotton MF; Liberty A; Torres-Escobar I; Gonzalez-Tome MI; Lissens J; Zaru L; Klauck I; Cambilargiu D; Pikora C; Correll TA
Pediatr Infect Dis J; 2018 Jun; 37(6):e149-e156. PubMed ID: 29206747
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.
McDonald C; Uy J; Hu W; Wirtz V; Juethner S; Butcher D; McGrath D; Farajallah A; Moyle G
AIDS Patient Care STDS; 2012 May; 26(5):259-64. PubMed ID: 22404426
[TBL] [Abstract][Full Text] [Related]
8. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
[TBL] [Abstract][Full Text] [Related]
9. Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up.
Laprise C; Baril JG; Dufresne S; Trottier H
AIDS Patient Care STDS; 2013 Jul; 27(7):378-86. PubMed ID: 23829329
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
Lê MP; Mandelbrot L; Descamps D; Soulié C; Ichou H; Bourgeois-Moine A; Damond F; Lariven S; Valantin MA; Landman R; Faucher P; Tubiana R; Duro D; Meier F; Legac S; Bourse P; Mortier E; Dommergues M; Calvez V; Matheron S; Peytavin G
Antivir Ther; 2015; 20(5):507-13. PubMed ID: 25599649
[TBL] [Abstract][Full Text] [Related]
12. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
[TBL] [Abstract][Full Text] [Related]
13. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
[TBL] [Abstract][Full Text] [Related]
14. Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.
Postorino MC; Prosperi M; Focà E; Quiros-Roldan E; Di Filippo E; Maggiolo F; Borghetti A; Ladisa N; Di Pietro M; Gori A; Sighinolfi L; Pan A; Mazzini N; Torti C
BMC Infect Dis; 2017 Mar; 17(1):212. PubMed ID: 28298195
[TBL] [Abstract][Full Text] [Related]
15. Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.
Castagna A; Spagnuolo V; Galli L; Vinci C; Nozza S; Carini E; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Lazzarin A;
AIDS; 2014 Sep; 28(15):2269-79. PubMed ID: 25058680
[TBL] [Abstract][Full Text] [Related]
16. Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.
Cure S; Bianic F; Espinas C; Hardy H; Rosenblatt L; Juday T
PLoS One; 2015; 10(5):e0124666. PubMed ID: 25938588
[TBL] [Abstract][Full Text] [Related]
17. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.
Rodríguez-Nóvoa S; Martín-Carbonero L; Barreiro P; González-Pardo G; Jiménez-Nácher I; González-Lahoz J; Soriano V
AIDS; 2007 Jan; 21(1):41-6. PubMed ID: 17148966
[TBL] [Abstract][Full Text] [Related]
18. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
Pérez-Elías MJ; Gatell JM; Flores J; Santos J; Vera-Médez F; Clotet B; Moreno A; Pérez-Molina JA; Vendrell B; Serrano O
HIV Clin Trials; 2009; 10(4):269-75. PubMed ID: 19723614
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Broder MS; Chang EY; Bentley TG; Juday T; Uy J
J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
[TBL] [Abstract][Full Text] [Related]
20. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
J Med Econ; 2016; 19(4):386-96. PubMed ID: 26640980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
